))
Behind the Science: CEO of ScanCell, Lindy Durrant on the Company's Breakthrough Antibody Evaluation
Manage episode 438041099 series 3502513
Contenido proporcionado por Karl West. Todo el contenido del podcast, incluidos episodios, gráficos y descripciones de podcast, lo carga y proporciona directamente Karl West o su socio de plataforma de podcast. Si cree que alguien está utilizando su trabajo protegido por derechos de autor sin su permiso, puede seguir el proceso descrito aquí https://es.player.fm/legal.
In this episode of the All Points West podcast, we sit down with Lindy Durrant, the founder and CEO of AIM-listed ScanCell. Since co-founding ScanCell in 1997, Lindy has been at the forefront of developing groundbreaking immunotherapies for cancer and infectious diseases. With over 25 years of experience in translational research, she has played a pivotal role in bringing monoclonal antibodies and cancer vaccines from the lab to clinical trials. We discuss the rapidly growing immuno-oncology market, the potential of ScanCell's GlyMab platform, and what the future holds for cancer treatment.
29 episodios
Compartir
